Multi-Omics · Proteomics

Precision Begins at
the Proteome

Mass Spectrometry · Protein Expression · Biomarker Discovery · Clinical Translation · Structural Analysis · Drug Targets

20K+

Human Proteins

1M+

Proteoforms

100%

Patient-Centered

Board

Certified Standard

Department Overview

Pro·te·o·mics

/ ˌprōtēˈōmiks / · noun

noun · precision science

The large-scale study of the complete set of proteins expressed by a genome, cell, tissue, or organism at a given time encompassing their structure, function, quantity, and interactions in the context of health and disease.

Origin

From Latin proteinus (protein, first) + Greek -ome (complete set). The term was coined by Marc Wilkins in 1994 to describe the entire protein complement expressed by a genome recognizing that proteins, not genes, are the primary executors of biological function.

The Proteomics Department at the American Board of Precision Medicine bridges the gap between genetic blueprint and biological reality - training clinicians to interrogate the proteome as the functional layer where disease manifests, drug targets reside, and biomarkers are born.

From mass spectrometry-based protein profiling and post-translational modification analysis to structural proteomics and protein-protein interaction mapping, this department equips physicians to interpret the dynamic protein landscape that genomics alone cannot reveal translating proteomic signatures into diagnostic, prognostic, and therapeutic decisions.

Because proteins are the direct mediators of cellular function and the primary targets of most therapeutics, proteomics occupies a uniquely actionable position in the multi-omics stack and at ABOPM, it is taught as the bridge between molecular biology and clinical practice.

20K+

Human Proteins

1M+

Proteoforms

∞

Clinical Possibilities

Proteomics Department · ABOPM

Where the Proteome Meets
Clinical Purpose

The Proteomics Department at ABOPM exists at the intersection of protein science and patient care - training physicians to decode the proteome, apply its insights, and transform outcomes across every clinical specialty.

Proteomic Discovery

Advancing research in mass spectrometry-based protein profiling, post-translational modification analysis, and protein–protein interaction mapping - illuminating the functional molecules that drive cellular processes and disease pathogenesis.

Clinical Translation

Bridging proteomic laboratory science and bedside medicine developing board-certified frameworks for protein biomarker discovery, targeted therapy selection, and disease monitoring across oncology, autoimmunity, and cardiovascular medicine.

Physician Education

Building the next generation of proteomics-fluent clinicians through rigorous board standards, interdisciplinary training, and collaboration across molecular medicine, oncology, rheumatology, and translational research.

"The proteome is where biology becomes action. The Proteomics Department at ABOPM trains physicians to read that action, interpret its clinical significance, and deliver care that meets patients at the molecular level."

American Board of Precision Medicine · Proteomics Department

Become a Member → Support Our Mission → Get Involved →

Proteomics Department · ABOPM

Translating the Proteome
Into Clinical Impact

The proteome is where the genome becomes function - the full complement of proteins that execute every biological process in the human body. Learning to read it is not optional for the future of medicine - it is foundational.

Proteomics equips clinicians to move beyond genetic potential and into biological reality - identifying the proteins that drive disease, serve as therapeutic targets, and act as the most direct molecular window into a patient's current health state.

By mastering proteomics, clinicians gain the power to:

01

Detect Disease Earlier

Identify disease-associated protein signatures and aberrant expression patterns before clinical symptoms manifest - enabling earlier intervention than genomic or clinical markers alone permit.

02

Select Targeted Therapies

Use proteomic profiling to match patients to targeted biologics, antibody therapies, and kinase inhibitors based on the precise protein drivers of their disease — not population averages.

03

Interpret Protein Biomarkers

Apply mass spectrometry data, post-translational modification profiles, and protein interaction networks as clinical biomarkers - translating complex proteomic data into confident, actionable decisions.

04

Monitor Treatment Response

Track proteome-level shifts as direct indicators of therapeutic efficacy and disease progression - capturing biological changes that genetics and imaging cannot detect in real time.

05

Lead Precision Care

Become the proteomics-fluent clinician your institution needs - positioned at the frontier of medicine where protein science meets measurable, life-changing patient impact.

Why Proteomics Fluency Is Non-Negotiable

The proteins are active. The clinical tools are ready. The question is, are you?

Patient Outcomes

Proteomics-guided therapy selection improves response rates, reduces toxicity from ill-matched treatments, and enables monitoring of disease at its most functionally relevant molecular level.

Future-Ready Practice

Protein-based diagnostics and targeted biologics now dominate oncology and autoimmune pipelines - clinicians who can't interpret proteomic data will be unable to lead the next generation of care.

Clinical Authority

Board certification in proteomics distinguishes you as a precision medicine leader capable of bridging molecular biology and therapeutic decision-making - a rare and increasingly essential skill set.

Interdisciplinary Impact

Proteomics spans every specialty: oncology, rheumatology, cardiology, neurology, and infectious disease giving you tools to decode disease biology across all of medicine's most complex clinical challenges.

Active research areas driving proteomic medicine forward:

01

Mass Spectrometry-Based Proteomics

Deploying data-independent acquisition (DIA) and tandem mass spectrometry to identify and quantify thousands of proteins simultaneously building comprehensive disease-associated protein atlases with unmatched depth and reproducibility.

02

Post-Translational Modification Profiling

Characterizing phosphorylation, ubiquitination, glycosylation, and acetylation patterns that regulate protein function revealing the signaling switches that drive cancer progression, immune activation, and metabolic disease.

03

Protein Biomarker Discovery & Validation

Identifying and clinically validating plasma, tissue, and single-cell protein signatures as early diagnostic, prognostic, and pharmacodynamic biomarkers across oncology, autoimmunity, and cardiovascular disease.

04

Protein Interaction Networks

Mapping the interactome - protein-protein interaction networks, co-immunoprecipitation data, and proximity labeling results to identify hub proteins, therapeutic vulnerabilities, and novel drug targets in disease pathways.

05

Single-Cell & Spatial Proteomics

Resolving protein expression at single-cell resolution and within tissue spatial context uncovering cellular heterogeneity, tumor microenvironment dynamics, and tissue-specific disease mechanisms invisible to bulk analysis.

Proteomics Research · ABOPM

Pushing the Frontier of Proteomic Science

The proteomics revolution is not a future event - it is happening now. Mass spectrometry-based protein profiling, post-translational modification analysis, and single-cell proteomics are actively reshaping how disease is detected, targeted, and monitored at the functional molecular level.

The ABOPM Proteomics Department positions clinicians at the center of this transformation equipping them with the scientific literacy, clinical frameworks, and board-certified credentials to lead proteomic medicine in any specialty.

$6.5B

Global proteomics market by 2027

20K+

Human proteins currently catalogued

60%

of drug targets are proteins

Explore Blog Topics → Read clinical insights, case studies & proteomics updates on our blog

Proteomics Department · ABOPM

Meet Our Leadership

Director of Proteomics

Director

Proteomics

Director of Proteomics

Rob Fraser, PhD

Scientist & Entrepreneur · Molecular Diagnostics & Personalized Medicine · Biotech Innovator

Scientist, entrepreneur, and biotech innovator spanning molecular diagnostics and personalized medicine - translating science into clinically actionable tools at scale.

Dr. Fraser is President, Chief Scientific Officer, and Co-founder of Molecular You Corporation, where he leads scientific strategy behind a multi-biomarker analytics platform. As founding CEO, he pioneered a cost-effective method to quantify hundreds of biomarkers from a single blood sample and integrate them with AI-enabled literature insights.

His training includes the University of Alberta, Harvard Medical School, and postdoctoral fellowships in Toronto and Strasbourg. He has held senior research roles at Sanofi, Xenon, Neuromed, and CDRD, and co-founded multiple companies including GenXys Health Care Systems, Mesentech Corporation, Contextual Genomics, and Microbiome Insights.

He has helped raise more than $50 million to support health tech ventures and continues to focus on translating science into clinically actionable tools. A former varsity swimmer and member of the Canadian National Water Polo Team, he remains active in philanthropy and health innovation.

CSO

Molecular You Corp.

$50M+

Health Tech Raised

5+

Companies Co-Founded

Connect on LinkedIn

Faculty Members

Our faculty roster is growing - announcements coming soon.

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Think you're the right fit for a faculty position?

Get Involved →

Genomics Department · ABOPM

Shaping the Future
of Precision Medicine

As precision medicine continues to evolve, genomics will play an increasingly central role in redefining how disease is understood, predicted, and treated at the molecular level.

The Genomics Department at ABOPM remains committed to advancing this field through scientific leadership, clinical innovation, and collaborative discovery. Together with our global community of physicians and researchers, we are helping shape the future of next-generation healthcare.

Explore Certification → Get Involved

Featured Insights

Insights Shaping
Precision Medicine

Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.

Multi-Omics Clinical Innovation Precision Prevention Physician Leadership

Precision Medicine in Oncology Isn’t the Future - It’s Already Late

Precision medicine in oncology is no longer a distant vision- it is a critical necessity. As cancer care evolves, biomarker-driven diagnostics, genomic sequencing, digital pathology, and AI-powered in... ...more

Precision Oncology

May 17, 2026•4 min read

Pharmacogenomics in Clinical Practice: Prescribing the Right Drug the First Time

Helping clinicians understand how genetic variation influences drug response ...more

Precision Medicine in Action

May 13, 2026•9 min read

Tumor Genomic Profiling: When Should It Be Used in Clinical Practice?

Tumor genomic profiling helps identify actionable mutations to guide targeted therapies and clinical decisions. Understanding when to use it is key to maximizing its impact in precision oncology. ...more

Precision Oncology

May 07, 2026•8 min read